SCHEMBL6316562

SCHEMBL6316562

CCc1ccc(-c2noc(N)c2C(=O)NCc2cccs2)s1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.57
SMN1; SMN2 Q16637 7/20 0.57
HPGD P15428 7/20 0.57
ALDH1A1 P00352 4/20 0.49
CYP1A2 P05177 3/20 0.49
CYP2C9 P11712 3/20 0.49
CYP2C19 P33261 3/20 0.49
CYP2D6 P10635 2/20 0.49
POLB P06746 2/20 0.48
NPC1 O15118 7/20 0.47
KMT2A Q03164 5/20 0.47
MEN1 O00255 4/20 0.47
LMNA P02545 3/20 0.43
TSHR P16473 1/20 0.43
MAPT P10636 3/20 0.43
KDM4E B2RXH2 2/20 0.43
GAA P10253 2/20 0.43
THRB P10828 2/20 0.43
GLA P06280 1/20 0.43
TP53 P04637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6315025 0.89 ALDH1A1 (0.53) RAB9ASMN1; SMN2HPGDALDH1A1CYP1A2
SCHEMBL6316464 0.86 HPGD (0.56) RAB9ASMN1; SMN2HPGDALDH1A1CYP1A2
SCHEMBL6317923 0.86 ALDH1A1 (0.48) RAB9ASMN1; SMN2HPGDALDH1A1CYP1A2
SCHEMBL6317805 0.85 GAA (0.48) RAB9ASMN1; SMN2HPGDALDH1A1CYP1A2
SCHEMBL6316409 0.82 HPGD (0.45) HPGDALDH1A1POLBNPC1LMNA
SCHEMBL6316605 0.82 ALDH1A1 (0.54) RAB9ASMN1; SMN2HPGDALDH1A1CYP1A2
SCHEMBL6314978 0.82 KMT2A (0.47) HPGDALDH1A1CYP1A2CYP2C19CYP2D6
SCHEMBL6318552 0.82 ALDH1A1 (0.50) RAB9ASMN1; SMN2HPGDALDH1A1CYP1A2
SCHEMBL6317726 0.82 HPGD (0.43) SMN1; SMN2HPGDALDH1A1POLBLMNA
SCHEMBL6317745 0.82 NPC1 (0.44) SMN1; SMN2HPGDALDH1A1CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
CN-1549714-A Aminoisoxazole derivatives active as kinase inhibitors 2004-11-24 CN claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 RAB9A 1754/4885SMN1; SMN2 2766/4885HPGD 2923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.